 |
|
 |
Mini-symposia
Session I |
Wednesday, October 15, 2003
Natcher Conference Center |
|
Using the New Omics
in the Molecular Epidemiology of Chronic Diseases:
Emergence of a New Paradigm |
10:30 a.m. - 12:00 p.m. |
Co-chaired
by: |
| Nathaniel
Rothman, M.D., M.P.H., M.H.S.
Senior Investigator, Occupational and Environmental
Epidemiology Branch,
Division of Cancer Epidemiology and Genetics
(DCEG), NCI
Stephen Chanock, M.D.
Head, Section on Genetic Variation, Pediatric
Oncology Branch, CCR, NCI and
Director, Core Genotyping Facility, Advanced
Technology Center, DCEG, NCI |
Balcony
A, Natcher Conference Center |
New opportunities to explore
the etiology of chronic disease, as well as
to improve
diagnosis and treatment, have evolved because
of new developments in both
technical and analytical approaches to surveying
increasingly larger portions of the
expressed proteome and genome. Previously,
biologically-based hypothesisdriven
research has been the hallmark of investigating
chronic disease but with
the advent of technologies that allow the
broad interrogation of the proteome,
transcriptome and genome, essentially the
entire range of biologic processes can
now or soon will be analyzed. Though conceptually
very exciting, the task of
interpreting the avalanche of information
has raised serious questions as to how to
proceed down this course. In particular, the
shift in paradigm has altered the
relative importance of testing only hypotheses
with high priors. Results from
some of the initial applications of these
new technologies will be provided in the
context of cancer research. In addition, the
central issues of replication and
validation are undergoing transformation,
partly in response to the enormous
amounts of data generated. Specifically, new
strategies to minimize the potential
for false-positive findings will be discussed. |
Program |
Bench-to-Bedside Applications
of Clinical Proteomics
Co-directors of the NCI-FDA Clinical
Proteomics Program:
Lance A. Liotta, M.D., Ph.D., Chief, Laboratory
of Pathology, CCR, NCI
Emanuel F. Petricoin, Ph.D., Senior Principal
Investigator, DTP, CBER, FDA |
| |
Molecular Diagnosis and
Molecular Targets in Cancer by Gene Expression
Profiling
Louis M. Staudt, M.D., Ph.D., Chief, Lymphoid
Malignancies Section, Metabolism
Branch, CCR, NCI |
| |
The Trajectory of Applying
Genetic Variation to the Study of the Etiology
of Cancer
Stephen Chanock, M.D., Head, Section on Genetic
Variation, Pediatric Oncology
Branch, CCR, NCI and Director, Core Genotyping
Facility, Advanced Technology
Center, DCEG, NCI |
| |
The Problem and Challenge
of False Positive Findings in the Omics Era
Sholom Wacholder, Ph.D., Senior Investigator,
Biostatistics Branch, DCEG, NCI |
|
|
|
|
| |
|
|
